These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pipeline and key clinical candidates for these companies:
Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.
Recent news on these stocks:
November 17
Wolfe Research initiated coverage of Summit Therapeutics with a Peer Perform rating and no price target The firm’s analysis suggests the Harmoni-2 may not show an overall survival benefit, the analyst tells investors.
Hear more from InvestingChannel by signing up for The Spill.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with a Peer Perform at Wolfe Research
- Positive Outlook for Summit Therapeutics Amid Strategic Clinical Advancements
- Summit Therapeutics Reports Positive Phase III Trial Results
- Akeso to announces results from OS analysis of Phase III HARMONi-A study
- Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See